<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535418</url>
  </required_header>
  <id_info>
    <org_study_id>CFEM345EDE01</org_study_id>
    <nct_id>NCT00535418</nct_id>
  </id_info>
  <brief_title>Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers</brief_title>
  <official_title>Pre-operative Hormone Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer: An Uncontrolled Phase IIb/III Trial to Assess Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess optimal duration of pre-operative treatment with letrozole and to
      correlate clinical efficacy with appropriate surrogate markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <primary_completion_date type="Actual">July 2002</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>FEM345</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Female Breast Cancer patients with primary invasive breast cancer, histologically
             confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone
             (PgR) positive (Clinical Stage *T2, T3, T4a,b,c, N0, M0)

          2. Patients after menopause

          3. Tumor measurable by clinical examination, mammography and ultrasound

          4. Adequate bone marrow, renal and hepatic function

          5. A life expectancy of at least 6 months.

        Exclusion criteria:

          1. Prior treatment with aromatase inhibitors or antiestrogens.

          2. Uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or
             hyperthyroidism, Cushing´s Syndrome, Addison´s disease (treated or untreated),
             Patients with unstable angina, uncontrolled cardiac disease (e.g. Class II or IV New
             York Heart Association's Functional Classification).

          3. Patients with tumors in both breasts, evidence of inflammatory breast cancer or
             distant metastasis

          4. Patients who are eligible for breast conserving surgery.

          5. Concomitant anti-cancer treatments such as chemotherapy, immunotherapy/biological
             response modifiers (BRM's), endocrine therapy (including steroids), bisphosphonate
             therapy and radiotherapy. Patients who have received HRT will NOT be excluded,
             provided that HRT is discontinued at least 2 weeks prior to entry into the study.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/searchbystudyid.nov?studyId=CFEM345EDE01</url>
    <description>Novartis Clinical Trial Results Database</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>neoadjuvant treatment</keyword>
  <keyword>treatment duration</keyword>
  <keyword>Primary hormone receptor positive</keyword>
  <keyword>breast cancer in postmenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

